United Therapeutics Corporation (UTHR)
United Therapeutics Corporation reported revenue of $3.18B for the fiscal year ended Dec 31, 2025, up 10.6% from $2.88B the year before. Net income was $1.33B, a net margin of 41.9% (prior year: $1.20B). At the end of that fiscal year the company reported total assets of $7.88B and shareholders' equity of $7.10B.
Revenue
$3.18B
+10.6% vs prior year
Net income
$1.33B
Net margin 41.9%
Diluted EPS
$27.86
USD per share
Total assets
$7.88B
At Dec 31, 2025
Equity
$7.10B
At Dec 31, 2025
Shares outstanding
43M
As of Jul 29, 2026
Explore United Therapeutics Corporation's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Aug 5, 2026
- 10-QFiled May 6, 2026
- 10-KFiled Feb 25, 2026
- 10-QFiled Oct 29, 2025
- 10-QFiled Jul 30, 2025
- 10-QFiled Apr 30, 2025
Source: SEC EDGAR XBRL company facts for CIK 1082554 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.